Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02
U.S. Biotech Industry Analysis
UpdatedJun 04, 2024
DataAggregated Company Financials
Companies573
- 7D0.6%
- 3M-4.9%
- 1Y6.3%
- YTD0.1%
The Biotech is pretty flat in the last 7 days, but Insmed has stood out, gaining 154%. As for the the longer term, the industry is up 6.3% over the past 12 months. Looking forward, earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 04 Jun 2024 | US$1.1t | US$164.6b | -US$26,680,256,870.37 | 27.7x | -42.1x | 6.8x |
| Thu, 02 May 2024 | US$1.1t | US$165.0b | -US$26,426,226,136.78 | 23.2x | -41x | 6.6x |
| Sat, 30 Mar 2024 | US$1.2t | US$164.4b | -US$23,362,713,195.15 | 20.8x | -50.5x | 7.2x |
| Mon, 26 Feb 2024 | US$1.2t | US$166.6b | -US$21,694,939,476.21 | 10.8x | -54.3x | 7.1x |
| Wed, 24 Jan 2024 | US$1.4t | US$204.7b | -US$22,529,001,992.00 | 18.1x | -63.5x | 7x |
| Fri, 22 Dec 2023 | US$1.3t | US$204.8b | -US$22,148,191,573.00 | 19x | -60x | 6.5x |
| Sun, 19 Nov 2023 | US$1.2t | US$204.7b | -US$22,079,556,420.00 | 18.1x | -54.7x | 5.9x |
| Tue, 17 Oct 2023 | US$1.3t | US$207.4b | -US$13,067,799,538.00 | 17.3x | -97.1x | 6.1x |
| Thu, 14 Sep 2023 | US$1.3t | US$207.5b | -US$12,611,945,630.00 | 17.6x | -101.4x | 6.2x |
| Sat, 12 Aug 2023 | US$1.3t | US$207.7b | -US$12,540,100,481.00 | 17.1x | -102.7x | 6.2x |
| Mon, 10 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Wed, 07 Jun 2023 | US$1.1t | US$185.9b | -US$16,017,335,337.00 | 11.6x | -71.1x | 6.1x |
| Fri, 05 May 2023 | US$1.2t | US$193.7b | -US$11,169,713,239.00 | 14.5x | -103.6x | 6x |
| Sun, 02 Apr 2023 | US$1.2t | US$217.0b | -US$5,990,852,997.00 | 14.3x | -193.4x | 5.3x |
| Tue, 28 Feb 2023 | US$1.1t | US$199.8b | -US$4,402,706,584.00 | 14.3x | -256.6x | 5.7x |
| Thu, 26 Jan 2023 | US$1.2t | US$203.9b | US$1.8b | 14.7x | 652x | 5.7x |
| Sat, 24 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 703.1x | 5.7x |
| Mon, 21 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.7x | 887.8x | 5.6x |
| Wed, 19 Oct 2022 | US$1.1t | US$206.2b | US$5.5b | 15.8x | 195.6x | 5.2x |
| Fri, 16 Sep 2022 | US$1.1t | US$206.6b | US$5.7b | 15x | 187.8x | 5.2x |
| Sun, 14 Aug 2022 | US$1.1t | US$206.8b | US$7.2b | 15.9x | 155.3x | 5.4x |
| Tue, 12 Jul 2022 | US$1.1t | US$211.3b | US$10.7b | 16.8x | 101.6x | 5.1x |
| Thu, 09 Jun 2022 | US$1.0t | US$212.7b | US$11.3b | 16.6x | 90.2x | 4.8x |
| Sat, 07 May 2022 | US$1.0t | US$207.7b | US$9.9b | 15.5x | 101.7x | 4.8x |
| Mon, 04 Apr 2022 | US$1.3t | US$227.1b | US$14.5b | 18.7x | 89.3x | 5.7x |
| Wed, 02 Mar 2022 | US$1.2t | US$223.0b | US$9.9b | 19.3x | 123.7x | 5.5x |
| Fri, 28 Jan 2022 | US$1.2t | US$212.2b | US$2.5b | 22.5x | 477.6x | 5.6x |
| Sun, 26 Dec 2021 | US$1.4t | US$212.0b | US$2.8b | 26.1x | 522.3x | 6.8x |
| Tue, 23 Nov 2021 | US$1.4t | US$211.8b | US$3.3b | 26.2x | 444.1x | 6.8x |
| Thu, 21 Oct 2021 | US$1.5t | US$196.4b | -US$2,593,140,913.00 | 24x | -569x | 7.5x |
| Sat, 18 Sep 2021 | US$1.6t | US$196.3b | -US$2,218,809,765.00 | 25x | -723.9x | 8.2x |
| Mon, 16 Aug 2021 | US$1.5t | US$197.0b | -US$1,662,914,785.58 | 22.8x | -922.5x | 7.8x |
Price to Earnings Ratio
-1810.8x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.61% | |
| Healthcare | 0.077% | |
| Biotech | 0.57% | |
| Biotech | 0.57% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| INSM Insmed | US$55.94 | 154.3% +US$5.7b | 187.3% | PS28.6x | |
| ABBV AbbVie | US$160.19 | 2.0% +US$5.5b | 17.0% | PE47.5x | |
| SMMT Summit Therapeutics | US$8.84 | 161.5% +US$3.8b | 375.3% | PB140.4x | |
| VRTX Vertex Pharmaceuticals | US$470.18 | 2.9% +US$3.4b | 40.6% | PE30.2x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x |